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T he receptor for advanced glycation end products,  RAGE (gene name: AGER),  a single-pass type I 
transmembrane protein belonging to the immunoglob-
ulin (Ig) superfamily [1],  has critical roles in a broad 
range of inflammatory,  degenerative and hyper-prolif-
erative diseases [2-5].  The structure-based dimension 
of extracellular RAGE is composed of an N-terminal 
Ig-V following Ig-C1 and Ig-C2,  displaying a unique 
binding ability to multiple substances including ligands 
such as advanced glycation end products (AGEs) [2],  
Acta Med.  Okayama,  2017
Vol.  71,  No.  6,  pp.  459-465
CopyrightⒸ 2017 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Review
Signal Diversity of Receptor for Advanced Glycation End Products
Masakiyo Sakaguchia＊§,  Rie Kinoshitaa,  Endy Widya Putrantob,  I Made Winarsa Rumaa,c,d,   
I Wayan Sumardikaa,c,  Chen Youyia,  Naoko Tomonobua,  Ken-ichi Yamamotoa,  and Hitoshi Murataa
Departments of aCell Biology and cPharmacology,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan,  bFaculty of Medicine,  Universitas Gadjah Mada,   
Yogyakarta 55281,  Indonesia,  dFaculty of Medicine,  Udayana University,  Denpasar 80232,  Bali,  Indonesia
The receptor for advanced glycation end products (RAGE) is involved in inflammatory pathogenesis.  It func-
tions as a receptor to multiple ligands such as AGEs,  HMGB1 and S100 proteins,  activating multiple intracel-
lular signaling pathways with each ligand binding.  The molecular events by which ligand-activated RAGE con-
trols diverse signaling are not well understood,  but some progress was made recently.  Accumulating evidence 
revealed that RAGE has multiple binding partners within the cytoplasm and on the plasma membrane.  It was 
first pointed out in 2008 that RAGE’s cytoplasmic tail is able to recruit Diaphanous-1 (Dia-1),  resulting in the 
acquisition of increased cellular motility through Rac1/Cdc42 activation.  We also observed that within the 
cytosol,  RAGE’s cytoplasmic tail behaves similarly to a Toll-like receptor (TLR4)-TIR domain,  interacting with 
TIRAP and MyD88 adaptor molecules that in turn activate multiple downstream signals.  Subsequent studies 
demonstrated the presence of an alternative adaptor molecule,  DAP10,  on the plasma membrane.  The cou-
pling of RAGE with DAP10 is critical for enhancing the RAGE-mediated survival signal.  Interestingly,  RAGE 
interaction on the membrane was not restricted to DAP10 alone.  The chemotactic G-protein-coupled receptors 
(GPCRs) formyl peptide receptors1 and 2 (FPR1 and FPR2) also interacted with RAGE on the plasma mem-
brane.  Binding interaction between leukotriene B4 receptor 1 (BLT1) and RAGE was also demonstrated.  All of 
the interactions affected the RAGE signal polarity.  These findings indicate that functional interactions between 
RAGE and various molecules within the cytoplasmic area or on the membrane area coordinately regulate multi-
ple ligand-mediated RAGE responses,  leading to typical cellular phenotypes in several pathological settings.  
Here we review RAGE’s signaling diversity,  to contribute to the understanding of the elaborate functions of 
RAGE in physiological and pathological contexts.
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high-mobility group box 1 (HMGB1) [6] and S100 fam-
ily proteins [7].  In several pathological settings,  upon 
binding to ligands,  RAGE activates multiple intracellu-
lar signaling pathways involving in the small GTPase 
Rac1/Cdc42,  Ras-mediated extracellular signal-regu-
lated kinase 1/2 (ERK1/2),  Akt,  stress-activated protein 
kinase/c-Jun-NH2-terminal kinase (SAPK/JNK),  p38 
MAP kinase,  NF-κB transcription factor and caspases 
despite its very short cytoplasmic tail [8-12].
Although RAGE has long been recognized for its 
significant contribution to inflammatory pathogenesis,  
the innate mechanisms by which it regulates signal 
polarity in correlation to typical pathogenesis have not 
been systematically mapped out.  Recent studies have 
gradually uncovered the complex mechanisms of RAGE 
in controlling multiple signals.  A breakthrough has 
come from the identification and characterization of 
RAGE-binding proteins in the absence of extracellular 
ligands.  In this review,  we discuss newly identified 
RAGE-binding proteins and their roles in RAGE-
mediated signals and functions.
Signal Transducers Act through Binding with 
the RAGE Cytoplasmic Domain
The question of how the RAGE cytoplasmic tail 
induces the activation of multiple signaling pathways 
upon the binding of ligands that correspond to diverse 
cellular events (such as growth,  migration,  invasion,  
apoptosis and the appearance of a secretory phenotype 
in correlation to inflammatory cytokines and chemok-
ines) has long been a puzzle,  since the cytoplasmic tail 
of RAGE is very short (41 aa).  In addition,  the tail has 
no outstanding composition in its domain and no 
inclusion of tyrosine as a phosphorylation target.  This 
irregularity may be explained by the presence of various 
types of binding adaptors that can be expected to be 
critical in the process of RAGE-mediated signal trans-
ductions.
In 2008,  Hudson et al.  first tried to identify the 
adaptor molecules by using a yeast two-hybrid system 
with the human RAGE cytoplasmic domain as “bait” 
[13].  This approach led to the discovery of an import-
ant binding partner,  Diaphanous-1 (Dia-1).  Their study 
revealed that Dia-1 interaction induces cellular migra-
tion through the activation of certain small guanine 
nucleotide triphosphatases (GTPases),  i.e.,  Rac1 and 
Cdc42.  This novel finding is in accordance with the 
innate function of Dia-1,  since the protein plays a sig-
nificant role in the regulation of cytoskeletal organiza-
tion that leads to the promotion of cellular motility [14].
As there are no obvious domains or motifs associ-
ated with the guanyl-nucleotide exchange function in 
Dia-1,  it is believed that the addition of a guanine 
nucleotide exchange factor (GEF) that catalyzes the 
change from GDP to the active form of GTP in the 
small GTPase is needed for the activation of Rac1 and 
Cdc42 through the interaction of Dia-1 with the RAGE 
cytoplasmic tail.
In light of this idea,  we attempted to identify GEFs 
using an alternative method,  i.e.,  an immunoprecipita-
tion-liquid chromatography with tandem mass spec-
trometry (LC-MS/MS) procedure using overexpression 
of the epitope tagged-human RAGE cytoplasmic domain.  
Fortunately,  this approach enabled us to identify an 
atypical DOCK180-GEF,  DOCK7 [15].  We found that 
the activation of Cdc42 by the RAGE ligand S100B in 
U-87MG human glioma cells that expressed an 
increased phenotype in cellular migration was effec-
tively abrogated by the down-regulation of DOCK7.  
We thus showed that DOCK7 is also involved in the 
small GTPase-mediated migration axis of RAGE 
through interplay with the key molecule Dia-1.
It remains difficult to determine whether DOCK7 
directly or indirectly binds to RAGE via Dia-1,  since the 
preparation of the full length of a recombinant protein 
in an intact condition is a challenge due to the high 
molecular weight (2,140 aa) of DOCK7.  Further 
advanced studies are required to settle this complex 
issue,  but we will focus here on the interaction between 
Dia-1 and DOCK7 in the same RAGE signaling path-
way toward the regulation of cellular motility.
Another significant role of RAGE is the effective 
induction of inflammatory cytokines and chemokines.  
It has repeatedly been shown that there is a marked 
similarity between RAGE and Toll-like receptor 4 
(TLR4) in terms of downstream signaling [16 , 17],  
which has turned our attention to comparisons of the 
amino acid sequences of the RAGE short cytoplasmic 
tail and the TLR4 cytoplasmic Toll/interleukin-1 recep-
tor (TIR) homology domain,  which is a signal trans-
duction domain.  To our surprise,  a very similar 
sequence (termed the ‘RT sequence’ in this review) was 
present in both RAGE (QEEE starting at 379) and TLR4 
(QDED starting at 683) (Fig. 1A).  The RT sequence was 
also present in the same TIR domain of TLR2 as an imi-
tated form (QELE starting at 661) but not in the TIR 
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domain of TLR1 or TLR3.  TLR2 and TLR4 both use 
TIRAP and MyD88 as an adaptor complex for their sig-
naling to induce inflammatory cytokines [18-21].
This finding gave us the opportunity to correlate the 
role of RAGE signaling with the roles of TLR2 and 
TLR4.  Interestingly,  further investigation demon-
strated that a variant of the RT sequence in the TLR4-
TIR domain lost its ability to bind with TIRAP and 
MyD88 (our unpubl.  data),  and we suspected that the 
sequence also plays an important role in the recruit-
ment of adaptors beside the BB-loop sequence (an 
essential sequence for interactions between certain 
TLRs and their adaptor molecules [21]) in the TIR 
domain.  We succeeded in identifying other important 
adaptor molecules,  TIRAP and MyD88,  in the RAGE 
cytoplasmic domain and found that the RAGE-TIRAP/
MyD88 signaling axis led to the activation of NF-κB,  
resulting in the expression of genes related to the 
inflammatory response,  such as tumor necrosis fac-
tor-alpha (TNF-α) and interleukin (IL)-6 [22].
The recruitment of TIRAP and MyD88 to the RAGE 
cytoplasmic tail is highly enhanced by stimulation with 
RAGE ligands.  We next focused on modification events 
at the cytoplasmic domain of RAGE.  We found that the 
cytoplasmic domain of RAGE was phosphorylated at 
Ser391 by protein kinase C-zeta (PKCζ) upon the bind-
ing of ligands (Fig. 1B).  This suggests a crucial role for 
the residue in phosphorylation modification.
We subsequently observed that the phosphorylation 
greatly enhanced the affinity of RAGE to TIRAP and 
MyD88,  indicating that a higher negative charge at the 
Ser391 residue is crucial for efficient binding with 
TIRAP and MyD88 [22].  Notably,  when the residue is 
phosphorylated,  QS(391)EE becomes equivalent to 
QEEE or QDEE,  displaying high similarity to the RT 
sequence.  The duplicated RT sequence (Q followed by 
three successive negatively charged residues) may play a 
role in the enhanced interaction of TIRAP and MyD88 
with the RAGE intracellular domain regardless of the 
absence of the BB-loop (Fig. 1C).
Membrane Proteins Coupled with RAGE Act as 
RAGE Modulators for Downstream Signaling
The regulatory mechanism of RAGE-mediated 
diverse signaling may not only be dependent on cyto-
plasmic adaptors.  For instance,  after coupling,  a mem-
brane protein such as gp130 co-functions with the IL-6 
receptor,  triggering activation of the JAK-STAT signal-
ing pathway [23].  In accord with this concept,  we tried 
to identify any possible RAGE-interacting proteins on 
the plasma membrane.  We first attempted to analyze 
epitope-tagged RAGE-immunoprecipitates from the 
membrane fraction prepared from RAGE-overexpressed 
cells.  However,  no RAGE co-precipitated proteins 
yielded any promising candidates (our unpubl.  data).  
We therefore shifted our strategy to a candidate-based 
screening method using forced co-expression of RAGE 
and selected membrane proteins that were co-function-
ing with cytokine receptors.  This led to the identifica-
tion of DNAX-Activating Protein 10 (DAP10) [24] as a 
novel transmembrane adaptor for RAGE [25].
Our studies showed that DAP10 binding modulates 
RAGE-triggered signaling toward survival enhance-
ment via the PI3K-Akt pathway after RAGE ligand 
stimulation.  A tyrosine residue (86Y) in the YXXM 
motif [26] of the intracellular domain of DAP10 
recruited PI3K (p85) when phosphorylated,  and the 
event further activated the effector kinase Akt.  
Interestingly,  the formed RAGE-DAP10 heterodimer 
has the ability to recruit not only PI3K (p85) but also 
GRB2 and GRB7 (Fig. 2,  left side of the bottom panel).  
GRB2 and GRB7 are able to promote cellular prolifera-
tion via activation of the Ras-ERK1/2 pathway [27 , 28].  
These pathways (including Akt,  GRB2 and GRB7) seem 
to be dominant in certain epithelial cancer cells and 
keratinocytes in inflammatory psoriatic settings,  since 
DAP10 is upregulated in those cases.
Conversely,  we also found that RAGE favors its own 
dimer or multimer in the absence of DAP10 after RAGE 
ligand stimulation (Fig. 2,  upper panel).  In this case,  
especially in the case of strong stimulation of RAGE 
with high concentrations of ligands,  the downstream 
signal tends to shift toward the apoptotic pathway 
through TIRAP-MyD88-caspase 8.  As reported previ-
ously,  we observed that PKCζ,  which phosphorylates 
RAGE at Ser391,  is activated by autophosphorylation at 
Thr560 [29].  The homo-dimerization and homo-multi-
merization of RAGE resulted in the autophosphoryla-
tion of PKCζ at Thr560.  Thus,  the homo-dimerization 
and homo-multimerization of RAGE may readily 
induce PKCζ,  activation which in turn phosphorylates 
the RAGE cytoplasmic tail at Ser391,  eventually leading 
to advanced TIRAP and MyD88 recruitment.  The 
abundant DAP10 is readily able to function to prevent 
RAGE homo-dimerization and homo-multimerization 
[25].
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Independently or our work,  Slowik et al.  presented 
a very interesting result regarding the interaction of 
RAGE with G-protein-coupled receptors (GPCRs) [30].  
Their study started from the discovery of a functional 
implication between RAGE and formyl peptide recep-
tors (FPRs),  i.e.,  formyl peptide receptor 1 (FPR1) and 
formyl peptide receptor-like 1 (FPRL1,  also known as 
FPR2),  in the inflammatory response to neurodegener-
ative Alzheimer’s disease.  Slowik et al.  revealed physi-
ological interactions between RAGE and FPRs.  The 
interactions broadened the spectrum of ligand respon-
siveness to FPRs; i.e.,  RAGE ligands were also able to 
stimulate FPRs that were associated with increased lev-
els of ERK1/2 phosphorylation and an accelerated con-
sumption of cAMP in glial cells.
Interaction between GPCRs and RAGE may not be 
unusual.  It was reported that G-protein-coupled 
chemokine receptors,  CCR5 and CXCR4,  co-function 
with CD4 [31] (a well-known T-cell surface glycopro-
tein composed of multiple Ig domains like RAGE) for 
human immunodeficiency virus (HIV) infection.  
Knowing this,  Ichiki et al.  recently succeeded in iden-
tifying another GPCR,  leukotriene B4 receptor 1 (BLT1),  
as a RAGE partner on the cell surface [32].  Before their 
study,  although a crucial role of BLT1 in promoting 
inflammation was well known,  interactive proteins that 
modulate the pro-inflammatory function of BLT1 
remained largely unidentified.  The solution reported by 




Fig. 1　 A unique feature in the amino acid (aa) 
sequence of the human RAGE cytoplasmic tail.  A,  
Comparison of sequences in the human RAGE cyto-
plasmic domain and the cytoplasmic TIR domains of 
TLR1-4.  The location of the BB-loop is shown in each 
TIR domain.  The RT sequence in human RAGE is 
marked by underlining.  The RT sequence appears as 
imitated forms in the cytoplasmic TIR domains in TLR2 
and TLR4 but not in those of TLR1 and TLR3: B,  
Alignment of the aa sequences of the human,  mouse,  
guinea pig,  rat,  rabbit,  dog and cat RAGE cytoplasmic 
domains.  The phosphorylatable aa residues in the 
human sequence are marked by dots.  The position at 
Ser391 in the human sequence is highly conserved 
among all species examined and is phosphorylated by 
PKCζ,  which is marked by a star: C,  Duplicated 
appearance of the RT sequence (underlined sites) in the 
human RAGE cytoplasmic domain after phosphorylation 
at Ser391 (star).
Ichiki et al.  was the novel finding of RAGE-BLT1 inter-
action in neutrophils.  The results of their study clearly 
showed that RAGE binding regulates BLT1 signaling 
with positive and negative measures by controlling the 
key effector kinase,  ERK1/2.
Although RAGE has an ERK1/2-mediated suppres-
sive function for NF-κB,  it remarkably 
enhances ERK1/2-mediated chemotaxis 
in neutrophils in response to LTB4 stim-
ulation.  That raises the question of how 
ERK1/2 suppresses NF-κB activation.  
The accurate mechanism still remains to 
be clarified.  However,  some clues have 
come from investigations [33 , 34] in 
which it was revealed that ERK1/2 nega-
tively regulates NF-κB-mediated tran-
scription through its regulation of the 
phosphorylation of the NF-κB p65 sub-
unit or the important NF-κB cooperative 
protein,  TATA-box binding protein 
(TBP).  Thus,  similar mechanism(s) may 
act in neutrophils.  Taken together,  these 
findings strongly support the idea that 
RAGE acts as a novel modifier for the 
LTB4-BLT1 signaling pathway in inflam-
mation-associated pathological contexts 
(Fig. 2,  bottom panel).
Concluding remarks. In this 
review,  we have introduced critical 
RAGE-binding proteins located in the 
cytoplasm and on the plasma membrane 
that modulate RAGE-mediated signaling 
diversity.  Dia-1 and DOCK7 are 
recruited to the cytoplasmic tail of 
RAGE and activate Rac1 and Cdc42,  
resulting in an upregulation of cellular 
migration (Fig. 2,  upper panel).  The 
binding of both TIRAP and MyD88 
induces multiple signals for the activa-
tion of several kinases including IRAK4,  
p38,  JNK and IKKs.  These are known to 
link with several cellular processes,  such 
as the survival,  apoptosis and acquisi-
tion of the secretory phenotype of 
inflammatory cytokines (Fig. 2,  upper 
panel).  However,  under certain physio-
logical conditions,  specific signals seem 
to appear from ligand-stimulated RAGE 
in a cell type- and context-dependent manner.  This 
makes the mechanism of RAGE signal regulation more 
complex.  One clue to this mechanism may come from 
the expression levels of membrane adaptor molecules of 
RAGE.  We identified DAP10 as a transmembrane 
adaptor for RAGE that is necessary to regulate the 
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Fig. 2　 Transmitting signals from RAGE-dimer,  RAGE-multimer,  RAGE-DAP10 
complex,  and RAGE-BLT1 complex.  See the text for details.
RAGE downstream signaling for specific cellular pro-
cesses such as survival and proliferation via activation of 
the PI3K-Akt pathway and probably GRB2/7-Ras-
ERK1/2 too (Fig. 2,  bottom panel).
In addition,  Slowik et al.  and Ichiki et al.  identified 
FPRs and BLT1 as novel co-receptors of RAGE.  RAGE’s 
association with FPRs provides the FPRs’ side with a 
broad ligand spectrum in glial cells,  by which not only 
FPR ligands but also RAGE ligands lead to the active 
consumption of intracellular cAMP.  The decreased level 
of cAMP may indirectly cause neuronal cell death 
through modulation of the neuron-interacting glial cell 
function in neurodegenerative settings.  BLT1 interac-
tion with RAGE is a critical determiner for neutrophil 
function (Fig. 2,  bottom panel).  The LTB4 ligand-BLT1 
signals are modulated by RAGE in both negative and 
positive ways.  While the alternately activated ERK1/2 
suppresses the LTB4-BLT1-mediated activation of 
NF-κB,  which leads to inflammatory cytokine produc-
tion,  it dominantly regulates the LTB4-BLT1-mediated 
induction of chemotaxis.  We also speculate that the 
expression profiles for a series of proteins interacting 
with RAGE (including Dia-1,  DOCK7,  TIRAP,  
MyD88,  DAP10,  FPRs and BLT1) vary greatly depend-
ing on the cell type,  in which partially overlapping or 
interfering signals among adaptors and receptors may be 
produced.  This increasingly complicates the mecha-
nism of RAGE signal regulation in cells.  However,  we 
sincerely hope that the discovery of novel binding part-
ners for RAGE will lead to the gradual uncovering of 
RAGE’s elaborate signal mechanisms in both physio-
logical and pathological conditions.
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